Diabetes mellitus acute myocardiac infarction
Conditions
Interventions
Liraglutide
Placebo
Sponsors
Shin-Tokyo hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: he case that was treated for myocardial infarction to assume the left coronary arteries Diabetes which have already received a diabetes drugs or the person which became the diagnosis of diabetes during hospitalization The person who does not receive GLP-1 analog and the DPP-IV inhibitor so far
Exclusion criteria
Exclusion criteria: Case having a serious renal damage and liver damage(Cr>2.0mg/dl, T-Bil>3.0mg/dl, PT<60%, Alb<2.8mg/dl) CABG enforcement planned case Case within CABG enforcement three months Case contraindicated to the dosage of Liraflutide The case that is using insulin Case having a serious underlying disease (including a malignant tumor, an infectious disease, DIC) The case that infarction responsibility blood vessel is a bypass graft
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement degree of cardiac function expressed in EF(Teichholz method , Simpson method) and EDV at start of therapy, one week later, the time of a discharge, six months later | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change of the following item RBC, WBC, Hb, Ht, Plt, TC, LDL-C, TG, HDL-C, ALT, AST, ganma-GTP, CK, CK-MB, BUN, Cr, BS, HbA1c, 1,5-AG, BNP 2. Coronary angiography (QCA:Quantitative Coronary Analysis) at the time of start of therapy, before a discharge, six months later . 3.Improvement degree of cardiac function expressed by MRI 4.major adverse cardiac events 5.Hypoglycemia event | — |
Countries
Japan
Contacts
Public Contactkoji sakai
Shin-Tokyo hospital Endocrinolory and diabetes internal medicine
Outcome results
None listed